Back to Search Start Over

Additional file 3 of Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers

Authors :
Baldini, Capucine
Danlos, Francois-Xavier
Varga, Andreea
Texier, Matthieu
Halse, Heloise
Mouraud, Severine
Cassard, Lydie
Champiat, Stéphane
Signolle, Nicolas
Vuagnat, Perrine
Martin-Romano, Patricia
Michot, Jean-Marie
Bahleda, Rastislav
Gazzah, Anas
Boselli, Lisa
Bredel, Delphine
Grivel, Jonathan
Mohamed-Djalim, Chifaou
Escriou, Guillaume
Grynszpan, Laetitia
Bigorgne, Amelie
Rafie, Saloomeh
Abbassi, Alae
Ribrag, Vincent
Postel-Vinay, Sophie
Hollebecque, Antoine
Susini, Sandrine
Farhane, Siham
Lacroix, Ludovic
Parpaleix, Aurelien
Laghouati, Salim
Zitvogel, Laurence
Adam, Julien
Chaput, Nathalie
Soria, Jean-Charles
Massard, Christophe
Marabelle, Aurelien
Publication Year :
2022
Publisher :
figshare, 2022.

Abstract

Additional file 3: Supplementary Fig. 3. Illustration of multiplex chromogenic staining dedicated to myeloid cells. A Representative image displays a 500umx669um image after multispectral imaging and spectral unmixing (merged image). B All markers. C CD68 (pseudocoloured white). D DAPI nuclear marker (pseudocoloured blue). E CD163 (pseudocoloured green). F DC-LAMP (pseudocoloured magenta). G IDO1 (pseudocoloured yellow). H CD163 measurement was undertaken using Inform v2.2 software segmentation by pixel-based threshold. I CD163+ density in biopsies of patients with DCB or without DCB at baseline and C2D1 were not significantly different (Wilcoxon rank-sum test).

Details

Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....47aef4ddb891f3196fde9e30aeb26e29
Full Text :
https://doi.org/10.6084/m9.figshare.20252854